Targeting the PTP1B‐Bcr‐Abl1 interaction for the degradation of T315I mutant Bcr‐Abl1 in chronic myeloid leukemia

Small‐molecule‐induced degradation of mutant Bcr‐Abl1 provides a potential approach to overcome Bcr‐Abl1 tyrosine kinase inhibitor (TKI)‐resistant chronic myeloid leukemia (CML). Our previous study reported that a synthetic steroidal glycoside SBF‐1 showed remarkable anti‐CML activity by inducing th...

Descripción completa

Detalles Bibliográficos
Autores principales: Elgehama, Ahmed, Wang, Yixuan, Yu, Ying, Zhou, Lin, Chen, Zhixiu, Wang, Liwei, Sun, Lijun, Gao, Jian, Yu, Biao, Shen, Yan, Xu, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807508/
https://www.ncbi.nlm.nih.gov/pubmed/36086954
http://dx.doi.org/10.1111/cas.15580

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807508/
https://www.ncbi.nlm.nih.gov/pubmed/36086954
http://dx.doi.org/10.1111/cas.15580

Ejemplares similares